AsiaNet  84088

NEW YORK, May 20, 2020 /PRNewswire=KYODO JBN/ --

    -- Together they will accelerate pharma clients' ability to bring

life-saving drugs to market through automation of medical and regulatory report

writing

Arria NLG, a leading provider of Natural Language Generation (NLG) technology,

today announced a collaboration with Glemser [

https://c212.net/c/link/?t=0&l=en&o=2808224-1&h=1262605700&u=https%3A%2F%2Fglemser.com%2F&a=Glemser

] Technologies to bring scalable automation solutions and major efficiencies to

healthcare and pharmaceuticals companies. Glemser will augment its global Life

Sciences Practice with a Natural Language Generation solution powered by Arria

technologies.

Photo - https://mma.prnewswire.com/media/1170187/Arria_NLG_Glemser.jpg  

Logo - https://mma.prnewswire.com/media/1164169/Arria_NLG_Logo.jpg

"Partnering with Arria to provide our clients with a way to automate the

writing of medical and regulatory reports was a natural choice," says Ray

Glemser, CEO. "NLG allows companies to save significant time and money while

increasing scalability and efficiency. Arria's break-through technology will

transform the way our customers bring life-saving drugs to market."

For over 30 years, Glemser has served life science clients by ensuring product

quality, improving regulatory compliance, and gaining operational efficiencies.

Glemser understands the unique challenges pharma companies face. Bringing a

drug to market can be a difficult, costly, and drawn-out process. Pharma

companies consistently have to report to regulators, governments, and consumers

on drug efficacy and safety. They are constantly under pressure to deliver

increased transparency, accountability, and innovation in their

drug-development process while staying in budget. Through strategic application

of technology, Glemser is committed to helping their clients modernize their

drug-development processes.

By automating some of the most time-consuming reporting — such as Clinical

Safety Reports (CSRs), Compliance Reports, Adverse Event Detection, and other

regulatory reports — firms can reap cost savings and free their medical writers

from the tedious work that is most prone to human error. Faster reporting means

they can present findings to regulatory authorities more quickly. Improved

accuracy early on in the reporting process means better compliance and faster

regulatory approval.

"We are in a crucial moment, given today's world events, when pharmaceutical

companies' ability to increase efficiencies and speed to market is more

important than ever," said Sharon Daniels, CEO of Arria. "Our collaboration

with Glemser is a path to expedite decision-making and time to insights for

those companies working to bring life-saving treatment to patients faster."

Learn more [

https://c212.net/c/link/?t=0&l=en&o=2808224-1&h=2781023476&u=https%3A%2F%2Fwww.arria.com%2Fglemser-portal%2F&a=Learn+more

]

ABOUT ARRIA

Arria is the global leader in Natural Language Generation (NLG)—which

transforms structured data into natural language. Through algorithms and

modeling, Arria software replicates the human process of expertly analyzing and

communicating data insights—dynamically turning data into written or spoken

narrative—at machine speed and massive scale.

Arria has the greatest concentration of NLG expertise in the world and has a

growing patent portfolio of 28 core NLG patents. Arria's rapidly growing group

of major international enterprise clients — including banking, financial

services, insurance, pharmaceutical, consumer product goods, news and media —

are now deploying NLG-driven automated reporting within their global

organizations using Arria's NLG Studio Platform. Additional information is

available at www.arria.com.

Media Contact: Lyndsee Manna

Senior Vice President, Business Development and Partnerships

Lyndsee.manna@arria.com

SOURCE  Arria NLG